Seagen (SGEN) Competitors

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Seagen shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 25.9% of Seagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Seagen's net margin of -32.61%. Vertex Pharmaceuticals' return on equity of 23.86% beat Seagen's return on equity.

Vertex Pharmaceuticals presently has a consensus target price of $555.17, indicating a potential upside of 29.82%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than Seagen.

Vertex Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Vertex Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Seagen has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.

In the previous week, Vertex Pharmaceuticals had 55 more articles in the media than Seagen. MarketBeat recorded 55 mentions for Vertex Pharmaceuticals and 0 mentions for Seagen. Vertex Pharmaceuticals' average media sentiment score of 0.92 beat Seagen's score of 0.00 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Regeneron Pharmaceuticals presently has a consensus target price of $826.59, indicating a potential upside of 14.64%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Seagen.

In the previous week, Regeneron Pharmaceuticals had 42 more articles in the media than Seagen. MarketBeat recorded 42 mentions for Regeneron Pharmaceuticals and 0 mentions for Seagen. Regeneron Pharmaceuticals' average media sentiment score of 0.69 beat Seagen's score of 0.00 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Seagen's net margin of -32.61%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Seagen's return on equity.

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Seagen has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.

Regeneron Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Seagen shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 25.9% of Seagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a consensus target price of $471.96, indicating a potential upside of 55.76%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Seagen.

In the previous week, Alnylam Pharmaceuticals had 31 more articles in the media than Seagen. MarketBeat recorded 31 mentions for Alnylam Pharmaceuticals and 0 mentions for Seagen. Alnylam Pharmaceuticals' average media sentiment score of 0.66 beat Seagen's score of 0.00 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Alnylam Pharmaceuticals has a net margin of 11.72% compared to Seagen's net margin of -32.61%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Seagen's return on equity.

Seagen has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Alnylam Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

84.3% of Seagen shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 25.9% of Seagen shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Biogen had 28 more articles in the media than Seagen. MarketBeat recorded 28 mentions for Biogen and 0 mentions for Seagen. Biogen's average media sentiment score of 0.79 beat Seagen's score of 0.00 indicating that Biogen is being referred to more favorably in the news media.

84.3% of Seagen shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 25.9% of Seagen shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biogen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Biogen has a net margin of 13.81% compared to Seagen's net margin of -32.61%. Biogen's return on equity of 12.83% beat Seagen's return on equity.

Seagen has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.

Biogen has a consensus target price of $214.23, indicating a potential upside of 12.35%. Given Biogen's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than Seagen.